CoChat
Sign Up
Cited by 76Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsOlfactory and Sensory Function Studies

Aging-associated sensory decline and Alzheimer’s disease

Open access
Hong, Suji, Baek, Seung-Hyun, Lai, Mitchell K. P., Arumugam, Thiruma V., Jo, Dong-Gyu·2024·Molecular Neurodegeneration
DOI 10.1186/s13024-024-00776-yPMC PMC11616278
Open this paper in CoChat — free accountOpen PDF

Abstract

Multisensory decline is common as people age, and aging is the primary risk of Alzheimer’s Disease (AD). Recent studies have begun to shed light on the possibility that age-related sensory decline could accelerate AD pathogenesis, or be a prodromal indicator of AD. Sensory impairments, specifically in taste and smell, often emerge before cognitive symptoms in AD, indicating their potential as early biomarkers. Olfactory dysfunction has been frequently associated with AD and may offer valuable insights into early detection. Hearing impairment is significantly associated with AD, but its causal impact on AD progression remains unclear. The review also discusses visual and tactile deficits in AD, including retinal thinning and changes in tactile perception, highlighting their links to disease progression. Focusing on molecular mechanisms, the review explores the roles of amyloid-β (Aβ) accumulation and tau protein pathology in sensory decline and their bidirectional relationship with AD. In summary, the evidence presented conclusively supports advocating for an integrated approach to understanding AD and sensory decline, to enhance early detection, implementing preventive strategies, and developing therapeutic interventions for AD. This approach underscores the significance of sensory health in addressing neurodegenerative diseases, particularly AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-024-00776-y

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Eleven ROIs have nominally significant correlations with both behaviors, including key sensory regions (VCP, VCS, and MGD) linked to early symptoms of AD in humans.

    “Eleven ROIs have nominally significant correlations with both behaviors (Supplementary Table 10), including key sensory regions (VCP, VCS, and MGD) linked to early symptoms of AD in humans71-74.”

    From Magnetic resonance microscopy maps widespread effects of Alzheimer’s disease on brain structures and behavior in mice (2026) · cites this paper as [71]

    The Background describes visual and auditory processing deficits at early stages of AD, and the Visual impairment section links visual-cortex pathology to AD-related visual disruption. The Auditory system section identifies the medial geniculate nucleus as an auditory pathway region, but our copy does not establish that VCP, VCS, and MGD individually are linked to early AD symptoms in humans. The eleven ROI correlations are attributed to the citing paper’s Supplementary Table 10, not to this source. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 314 · Cited by 76

Research works printed but not linked: 297

  1. [1]Peiffer AM, Hugenschmidt CE, Maldjian JA, Casanova R, Srikanth R, Hayasaka S, Burdette JH, Kraft RA, Laurienti PJ. Aging and the interaction of sensory cortical function and structure. Hum Brain Mapp. 2009;30(1):228–40. 18072271 PMC4485392 · DOI
  2. [3]Cho Y, Bae HG, Okun E, Arumugam TV, Jo DG. Physiology and pharmacology of amyloid precursor protein. Pharmacol Ther. 2022;235: 108122. 35114285 · DOI
  3. [4]Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2023;19(1):19–38. 36513730 · DOI · Paper page
  4. [5]Risacher SL, Wudunn D, Pepin SM, MaGee TR, McDonald BC, Flashman LA, Wishart HA, Pixley HS, Rabin LA, Paré N, et al. Visual contrast sensitivity in Alzheimer’s disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol Aging. 2013;34(4):1133–44. 23084085 PMC3545045 · DOI
  5. [6]Uhlmann RF, Larson EB, Koepsell TD. Hearing impairment and cognitive decline in senile dementia of the Alzheimer’s type. J Am Geriatr Soc. 1986;34(3):207–10. 3950288 · DOI
  6. [7]Murphy C. Olfactory and other sensory impairments in Alzheimer disease. Nat Rev Neurol. 2019;15(1):11–24. 30532084 · DOI · Paper page
  7. [8]Desikan RS, Sabuncu MR, Schmansky NJ, Reuter M, Cabral HJ, Hess CP, Weiner MW, Biffi A, Anderson CD, Rosand J, et al. Selective disruption of the cerebral neocortex in Alzheimer’s disease. PLoS ONE. 2010;5(9):e12853. 20886094 PMC2944799 · DOI
  8. [9]Zhang NK, Zhang SK, Zhang LI, Tao HW, Zhang GW. Sensory processing deficits and related cortical pathological changes in Alzheimer’s disease. Front Aging Neurosci. 2023;15: 1213379. 37649717 PMC10464619 · DOI · Paper page
  9. [10]Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, Rabinovici GD, Schott JM, Jones DT, Murray ME. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222–34. 33609479 PMC8056394 · DOI · Paper page
  10. [11]Risacher SL, WuDunn D, Tallman EF, West JD, Gao S, Farlow MR, Brosch JR, Apostolova LG, Saykin AJ. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. Brain Commun. 2020;2(1):fcaa019. 32309804 PMC7151662 · DOI
  11. [12]Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170–8. 22265212 PMC3740271 · DOI
  12. [13]McKee AC, Au R, Cabral HJ, Kowall NW, Seshadri S, Kubilus CA, Drake J, Wolf PA. Visual association pathology in preclinical Alzheimer disease. J Neuropathol Exp Neurol. 2006;65(6):621–30. 16783172 · DOI
  13. [14]Sinha UK, Hollen KM, Rodriguez R, Miller CA. Auditory system degeneration in Alzheimer’s disease. Neurology. 1993;43(4):779–85. 8469340 · DOI
  14. [15]Aylward A, Auduong P, Anderson JS, Zielinski BA, Wang AY, Weng C, Foster NL, Gurgel RK. Changes in the auditory association cortex in dementing illnesses. Otol Neurotol. 2020;41(10):1327–33. 32810019 · DOI
  15. [17]den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, Bergen AAB, Bouwman FH, Hoozemans JJ. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun. 2018;6(1):147. 30593285 PMC6309096 · DOI
  16. [18]Kusne Y, Wolf AB, Townley K, Conway M, Peyman GA. Visual system manifestations of Alzheimer’s disease. Acta Ophthalmol. 2017;95(8):e668–76. 27864881 · DOI
  17. [19]Cheng N, Bai L, Steuer E, Belluscio L. Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer’s disease model. J Neurosci. 2013;33(30):12208–17. 23884929 PMC3721835 · DOI
  18. [20]Ubeda-Bañon I, Saiz-Sanchez D, Flores-Cuadrado A, Rioja-Corroto E, Gonzalez-Rodriguez M, Villar-Conde S, Astillero-Lopez V, Cabello-de la Rosa JP, Gallardo-Alcañiz MJ, Vaamonde-Gamo J, et al. The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases. Transl Neurodegener. 2020;9(1):22. 32493457 PMC7271529 · DOI
  19. [21]Mantovani E, Zanini A, Cecchini MP, Tamburin S. The association between neurocognitive disorders and gustatory dysfunction: a systematic review and meta-analysis. Neuropsychol Rev. 2024;34(1):192–213. 36806051 PMC10920407 · DOI
  20. [22]Golde TE. Alzheimer’s disease: The journey of a healthy brain into organ failure. Mol Neurodegener. 2022;17(1):18. 10.1186/s13024-022-00512-3. PMC8898417 35248124 · DOI
  21. [24]Lantero-Rodriguez J, Camporesi E, Montoliu-Gaya L, Gobom J, Piotrowska D, Olsson M, Burmann IM, Becker B, Brinkmalm A, Burmann BM, et al. Tau protein profiling in tauopathies: a human brain study. Mol Neurodegener. 2024;19(1):54. 39026372 PMC11264707 · DOI
  22. [25]Chen M, Chen Y, Huo Q, Wang L, Tan S, Misrani A, Jiang J, Chen J, Chen S, Zhang J, et al. Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models. Mol Neurodegener. 2021;16(1):14. 33663578 PMC7934466 · DOI
  23. [26]Smith BC, D’Amico M. Sensory-based interventions for adults with dementia and Alzheimer’s Disease: a scoping review. Occup Ther Health Care. 2020;34(3):171–201. 31066598 · DOI
  24. [27]Chen X, Shi X, Wu Y, Zhou Z, Chen S, Han Y, Shan C. Gamma oscillations and application of 40-Hz audiovisual stimulation to improve brain function. Brain Behav. 2022;12(12):e2811. 36374520 PMC9759142 · DOI
  25. [28]Murdock MH, Yang CY, Sun N, Pao PC, Blanco-Duque C, Kahn MC, Kim T, Lavoie NS, Victor MB, Islam MR, et al. Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature. 2024;627(8002):149–56. 38418876 PMC10917684 · DOI
  26. [29]Manippa V, Palmisano A, Filardi M, Vilella D, Nitsche MA, Rivolta D, Logroscino G. An update on the use of gamma (multi)sensory stimulation for Alzheimer’s disease treatment. Front Aging Neurosci. 2022;14: 1095081. 36589536 PMC9797689 · DOI
  27. [30]D’Andrea F, Tischler V, Dening T, Churchill A. Olfactory stimulation for people with dementia: a rapid review. Dement (London). 2022;21(5):1800–24. PMC9243450 35435041 · DOI
  28. [31]Yang H, Luo Y, Hu Q, Tian X, Wen H. Benefits in Alzheimer’s disease of sensory and multisensory stimulation. J Alzheimers Dis. 2021;82(2):463–84. 34057081 · DOI
  29. [34]Jayakody DMP, Friedland PL, Martins RN, Sohrabi HR. Impact of aging on the Auditory System and related cognitive functions: a narrative review. Front Neurosci. 2018;12: 125. 29556173 PMC5844959 · DOI
  30. [35]Jayakody DMP, Menegola HK, Yiannos JM, Goodman-Simpson J, Friedland PL, Taddei K, Laws SM, Weinborn M, Martins RN, Sohrabi HR. The peripheral hearing and central auditory processing skills of individuals with subjective memory complaints. Front Neurosci. 2020;14: 888. 32982675 PMC7475691 · DOI
  31. [37]Eggermont JJ, Wang X. Temporal coding in auditory cortex. In: Winer JA, Schreiner CE, editors. The auditory cortex. New York: Springer; 2010. p. 309–28.
  32. [38]King AJ, Middlebrooks JC. Cortical representation of auditory space. In: Winer JA, Schreiner CE, editors. The auditory cortex. New York: Springer; 2010. p. 329–41.
  33. [39]Bregman AS. Auditory scene analysis: The perceptual organization of sound. Cambridge (MA): MIT Press; 1994.
  34. [40]Kraus KS, Canlon B. Neuronal connectivity and interactions between the auditory and limbic systems. Effects of noise and tinnitus. Hear Res. 2012;288(1–2):34–46. 22440225 · DOI
  35. [41]Kanwal JS, Ehret G. Communication sounds and their cortical representation. In: Winer JA, Schreiner CE, editors. The auditory cortex. New York: Springer; 2010. p. 343–67.
  36. [42]Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Capozzo R, Quaranta N, Pilotto A, Logroscino G. Age-related hearing impairment and frailty in Alzheimer’s disease: interconnected associations and mechanisms. Front Aging Neurosci. 2015;7:113. 26106327 PMC4460423 · DOI
  37. [43]Lin FR, Metter EJ, O’Brien RJ, Resnick SM, Zonderman AB, Ferrucci L. Hearing loss and incident dementia. Arch Neurol. 2011;68(2):214–20. 21320988 PMC3277836 · DOI
  38. [44]Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734. 28735855 · DOI · Paper page
  39. [46]Kay DW, Roth M, Beamish P. Old age mental disorders in newcastle upon TYNE. II. A study of possible social and medical causes. Br J Psychiatry. 1964;110:668–82. 14199809 · DOI
  40. [47]Dawes P, Emsley R, Cruickshanks KJ, Moore DR, Fortnum H, Edmondson-Jones M, McCormack A, Munro KJ. Hearing loss and cognition: the role of hearing AIDS, social isolation and depression. PLoS ONE. 2015;10(3): e0119616. 25760329 PMC4356542 · DOI
  41. [48]Maharani A, Dawes P, Nazroo J, Tampubolon G, Pendleton N. Longitudinal relationship between hearing Aid Use and cognitive function in older americans. J Am Geriatr Soc. 2018;66(6):1130–6. 29637544 · DOI · Paper page
  42. [49]Taljaard DS, Olaithe M, Brennan-Jones CG, Eikelboom RH, Bucks RS. The relationship between hearing impairment and cognitive function: a meta-analysis in adults. Clin Otolaryngol. 2016;41(6):718–29. 26670203 · DOI
  43. [50]Mamo SK, Nirmalasari O, Nieman CL, McNabney MK, Simpson A, Oh ES, Lin FR. Hearing care intervention for persons with dementia: a pilot study. Am J Geriatr Psychiatry. 2017;25(1):91–101. 27890543 PMC5164856 · DOI
  44. [51]Dawes P, Munro KJ. Hearing loss and dementia: where to from Here? Ear Hear. 2024;45(3):529–36. 38379156 PMC11008448 · DOI
  45. [52]Kim SY, Lim JS, Kong IG, Choi HG. Hearing impairment and the risk of neurodegenerative dementia: a longitudinal follow-up study using a national sample cohort. Sci Rep. 2018;8(1):15266. 30323320 PMC6189102 · DOI
  46. [53]Parker TD, Hardy C, Keuss S, Coath W, Cash DM, Lu K, Nicholas JM, James SN, Sudre C, Crutch S, et al. Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change. J Neurol Neurosurg Psychiatry. 2024;95(9):829–32. 38569877 PMC11347269 · DOI
  47. [54]Wang HF, Zhang W, Rolls ET, Li Y, Wang L, Ma YH, Kang J, Feng J, Yu JT, Cheng W. Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology. EBioMedicine. 2022;86: 104336. 36356475 PMC9649369 · DOI
  48. [55]Zheng M, Yan J, Hao W, Ren Y, Zhou M, Wang Y, Wang K. Worsening hearing was associated with higher β-amyloid and tau burden in age-related hearing loss. Sci Rep. 2022;12(1):10493. 35729211 PMC9212197 · DOI
  49. [56]de Flores R, Das SR, Xie L, Wisse LEM, Lyu X, Shah P, Yushkevich PA, Wolk DA. Medial temporal lobe networks in Alzheimer’s Disease: structural and molecular vulnerabilities. J Neurosci. 2022;42(10):2131–41. 35086906 PMC8916768 · DOI
  50. [57]Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, Graff-Radford J, Jones DT, Ferman TJ, Boeve BF, et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142(10):3230–42. 31501889 PMC6763736 · DOI · Paper page
  51. [58]Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, et al. Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47(12):2866–78. 32291510 PMC7567681 · DOI
  52. [61]Tarawneh HY, Jayakody DMP, Sohrabi HR, Martins RN, Mulders W. Understanding the relationship between age-related hearing loss and Alzheimer’s Disease: a narrative review. J Alzheimers Dis Rep. 2022;6(1):539–56. 36275417 PMC9535607 · DOI
  53. [62]Griffiths TD, Lad M, Kumar S, Holmes E, McMurray B, Maguire EA, Billig AJ, Sedley W. How can hear loss cause dementia? Neuron. 2020;108(3):401–12. 32871106 PMC7664986 · DOI
  54. [63]Ahmed MS, Priestley JB, Castro A, Stefanini F, Solis Canales AS, Balough EM, Lavoie E, Mazzucato L, Fusi S, Losonczy A. Hippocampal network reorganization underlies the formation of a temporal association memory. Neuron. 2020;107(2):283–e291286. 32392472 PMC7643350 · DOI
  55. [65]Diao T, Ma X, Zhang J, Duan M, Yu L. The correlation between hearing loss, especially high-frequency hearing loss and cognitive decline among the Elderly. Front Neurosci. 2021;15: 750874. 34867162 PMC8634596 · DOI
  56. [66]Kurata N, Schachern PA, Paparella MM, Cureoglu S. Histopathologic evaluation of vascular findings in the Cochlea in patients with Presbycusis. JAMA Otolaryngol Head Neck Surg. 2016;142(2):173–8. 26747711 · DOI
  57. [67]Sale A, Berardi N, Maffei L. Environment and brain plasticity: towards an endogenous pharmacotherapy. Physiol Rev. 2014;94(1):189–234. 24382886 · DOI · Paper page
  58. [68]Nithianantharajah J, Hannan AJ. The neurobiology of brain and cognitive reserve: mental and physical activity as modulators of brain disorders. Prog Neurobiol. 2009;89(4):369–82. 19819293 · DOI
  59. [70]Häggström J, Hederstierna C, Rosenhall U, Östberg P, Idrizbegovic E. Prognostic value of a test of central auditory function in conversion from mild cognitive impairment to dementia. Audiol Neurootol. 2020;25(5):276–82. 32388503 · DOI
  60. [71]Pronk M, Lissenberg-Witte BI, van der Aa HPA, Comijs HC, Smits C, Lemke U, Zekveld AA, Kramer SE. Longitudinal relationships between decline in speech-in-noise recognition ability and cognitive functioning: the longitudinal aging study Amsterdam. J Speech Lang Hear Res. 2019;62(4s):1167–87. 31026198 · DOI
  61. [72]Nixon G, Sarant JZ, Tomlin D, Dowell R. The relationship between peripheral hearing loss and higher order listening function on cognition in older australians. Int J Audiol. 2019;58(12):933–44. 31322017 · DOI
  62. [73]Mamo SK, Reed NS, Sharrett AR, Albert MS, Coresh J, Mosley TH, Knopman D, Lin FR, Deal JA. Relationship between domain-specific cognitive function and Speech-in-noise performance in older adults: the atherosclerosis risk in communities hearing pilot study. Am J Audiol. 2019;28(4):1006–14. 31825642 PMC7210433 · DOI
  63. [74]Jalaei B, Valadbeigi A, Panahi R, Nahrani MH, Arefi HN, Zia M, Ranjbar N. Central auditory processing tests as diagnostic tools for the early identification of elderly individuals with mild cognitive impairment. J Audiol Otol. 2019;23(2):83–8. 30727718 PMC6468277 · DOI
  64. [76]Manohar SG, Zokaei N, Fallon SJ, Vogels TP, Husain M. Neural mechanisms of attending to items in working memory. Neurosci Biobehav Rev. 2019;101:1–12. 30922977 PMC6525322 · DOI
  65. [78]Giroud N, Lemke U, Reich P, Matthes KL, Meyer M. The impact of hearing aids and age-related hearing loss on auditory plasticity across three months - an electrical neuroimaging study. Hear Res. 2017;353:162–75. 28705608 · DOI
  66. [79]Rigters SC, Bos D, Metselaar M, Roshchupkin GV, Baatenburg de Jong RJ, Ikram MA, Vernooij MW, Goedegebure A. Hearing impairment is associated with smaller brain volume in aging. Front Aging Neurosci. 2017;9:2. 28163683 PMC5247429 · DOI
  67. [80]Ren F, Ma W, Li M, Sun H, Xin Q, Zong W, Chen W, Wang G, Gao F, Zhao B. Gray matter atrophy is associated with cognitive impairment in patients with Presbycusis: a comprehensive morphometric study. Front Neurosci. 2018;12: 744. 30405333 PMC6205975 · DOI
  68. [81]Wayne RV, Johnsrude IS. A review of causal mechanisms underlying the link between age-related hearing loss and cognitive decline. Ageing Res Rev. 2015;23:154–66. 26123097 · DOI
  69. [82]Bucholc M, Bauermeister S, Kaur D, McClean PL, Todd S. The impact of hearing impairment and hearing aid use on progression to mild cognitive impairment in cognitively healthy adults: an observational cohort study. Alzheimers Dement (N Y). 2022;8(1):e12248. 35229022 PMC8863441 · DOI
  70. [83]Lin FR, Pike JR, Albert MS, Arnold M, Burgard S, Chisolm T, Couper D, Deal JA, Goman AM, Glynn NW, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023;402(10404):786–97. 37478886 PMC10529382 · DOI · Paper page
  71. [84]Cantuaria ML, Pedersen ER, Waldorff FB, Wermuth L, Pedersen KM, Poulsen AH, Raaschou-Nielsen O, Sørensen M, Schmidt JH. Hearing loss, hearing Aid Use, and risk of dementia in older adults. JAMA Otolaryngol Head Neck Surg. 2024;150(2):157–64. 38175662 PMC10767640 · DOI
  72. [85]Chen Y, Guan L, Chen J, Han K, Yu Q, Zhou J, Wang X, Ma Y, Ji X, Zhao Z, et al. Hearing intervention for decreasing risk of developing dementia in elders with mild cognitive impairment: study protocol of a multicenter randomized controlled trial for Chinese Hearing Solution for Improvement of Cognition in elders (CHOICE). Trials. 2023;24(1):767. 38017543 PMC10685713 · DOI
  73. [86]Murphy C, Schubert CR, Cruickshanks KJ, Klein BE, Klein R, Nondahl DM. Prevalence of olfactory impairment in older adults. JAMA. 2002;288(18):2307–12. 12425708 · DOI
  74. [87]Attems J, Walker L, Jellinger KA. Olfaction and aging: a Mini-review. Gerontology. 2015;61(6):485–90. 25968962 · DOI
  75. [88]Cha H, Kim S, Son Y. Associations between cognitive function, depression, and olfactory function in elderly people with dementia in Korea. Front Aging Neurosci. 2021;13:799897. 35087394 PMC8787281 · DOI
  76. [89]Schäfer L, Schriever VA, Croy I. Human olfactory dysfunction: causes and consequences. Cell Tissue Res. 2021;383(1):569–79. 33496882 PMC7835667 · DOI
  77. [90]Ekström IA, Rizzuto D, Grande G, Bellander T, Laukka EJ. Environmental air pollution and olfactory decline in aging. Environ Health Perspect. 2022;130(2):27005. 35139319 PMC8828267 · DOI
  78. [91]Vasavada MM, Martinez B, Wang J, Eslinger PJ, Gill DJ, Sun X, Karunanayaka P, Yang QX. Central olfactory dysfunction in Alzheimer’s disease and mild cognitive impairment: a functional MRI study. J Alzheimers Dis. 2017;59(1):359–68. 28671131 · DOI
  79. [92]Haehner A, Chen B, Espin M, Haussmann R, Matthes C, Desser D, Loessner L, Brandt MD, Donix M, Hummel T. Training with odors impacts hippocampal thickness in patients with mild cognitive impairment. J Alzheimers Dis. 2022;88(2):743–55. 35694924 · DOI
  80. [94]Firestein S. How the olfactory system makes sense of scents. Nature. 2001;413(6852):211–8. 11557990 · DOI
  81. [95]Nemati NN: A. S. BARWICH, Smellosophy: What the nose tells the mind, Cambridge, Massachusetts: Harvard University Press, 2020. Hist Philos Life Sci 2021;43(2):75.
  82. [96]Ramachandran VS, editor. Encyclopedia of the human brain. San Diego (CA): Academic Press; 2002.
  83. [97]Sahay A, Wilson DA, Hen R. Pattern separation: a common function for new neurons in hippocampus and olfactory bulb. Neuron. 2011;70(4):582–8. 21609817 PMC3109085 · DOI · Paper page
  84. [98]Attems J, Walker L, Jellinger KA. Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014;127(4):459–75. 24554308 · DOI
  85. [99]Kovács T, Cairns NJ, Lantos PL. Olfactory centres in Alzheimer’s disease: olfactory bulb is involved in early Braak’s stages. NeuroReport. 2001;12(2):285–8. 11209936 · DOI
  86. [100]Arnold SE, Lee EB, Moberg PJ, Stutzbach L, Kazi H, Han LY, Lee VM, Trojanowski JQ. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol. 2010;67(4):462–9. 20437581 PMC2864948 · DOI
  87. [101]Son G, Jahanshahi A, Yoo SJ, Boonstra JT, Hopkins DA, Steinbusch HWM, Moon C. Olfactory neuropathology in Alzheimer’s disease: a sign of ongoing neurodegeneration. BMB Rep. 2021;54(6):295–304. 34162463 PMC8249876 · DOI
  88. [102]Wilson RS, Schneider JA, Arnold SE, Tang Y, Boyle PA, Bennett DA. Olfactory identification and incidence of mild cognitive impairment in older age. Arch Gen Psychiatry. 2007;64(7):802–8. 17606814 · DOI
  89. [103]Park H, Kim H, Kim S, Cha H: The Association between Olfactory Function and Cognitive Impairment in Older Persons with Cognitive Impairments: A Cross-Sectional Study. Healthcare (Basel). 2021;9(4):399. PMC8065920 33916102
  90. [104]Yan Y, Aierken A, Wang C, Song D, Ni J, Wang Z, Quan Z, Qing H. A potential biomarker of preclinical Alzheimer’s disease: the olfactory dysfunction and its pathogenesis-based neural circuitry impairments. Neurosci Biobehav Rev. 2022;132:857–69. 34810025 · DOI
  91. [105]Jacobson PT, Vilarello BJ, Tervo JP, Waring NA, Gudis DA, Goldberg TE, Devanand DP, Overdevest JB. Associations between olfactory dysfunction and cognition: a scoping review. J Neurol. 2024;271(3):1170–203. PMC11144520 38217708
  92. [106]Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer’s disease. Biol Psychiatry. 2008;64(10):871–9. 18723162 PMC2613777 · DOI
  93. [107]Olofsson JK, Larsson M, Roa C, Wilson DA, Jonsson Laukka E. Interaction between odor identification deficit and APOE4 predicts 6-Year cognitive decline in elderly individuals. Behav Genet. 2020;50(1):3–13. 31760549 PMC6941999 · DOI
  94. [108]Dintica CS, Marseglia A, Rizzuto D, Wang R, Seubert J, Arfanakis K, Bennett DA, Xu W. Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. Neurology. 2019;92(7):e700-9. 30651382 PMC6382360 · DOI
  95. [109]Zhu L, Wang Z, Du Z, Qi X, Shu H, Liu D, Su F, Ye Q, Liu X, Zhou Z, et al. Impaired parahippocampal gyrus-orbitofrontal cortex circuit associated with visuospatial memory deficit as a potential biomarker and interventional approach for Alzheimer Disease. Neurosci Bull. 2020;36(8):831–44. 32350798 PMC7410893 · DOI
  96. [110]Aminoff EM, Kveraga K, Bar M. The role of the parahippocampal cortex in cognition. Trends Cogn Sci. 2013;17(8):379–90. 23850264 PMC3786097 · DOI
  97. [111]Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32(3):489–502. 6463130 · DOI · Paper page
  98. [113]Masaoka Y, Pantelis C, Phillips A, Kawamura M, Mimura M, Minegishi G, Homma I. Markers of brain illness may be hidden in your olfactory ability: a Japanese perspective. Neurosci Lett. 2013;549:182–5. 23769725 · DOI
  99. [114]Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol. 1998;55(1):84–90. 9443714 · DOI · Paper page
  100. [115]Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer’s disease and Parkinson’s disease on olfaction: a meta-analysis. Behav Brain Res. 2012;231(1):60–74. 22414849 · DOI
  101. [116]Doty RL. Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol. 2017;16(6):478–88. 28504111 · DOI
  102. [117]Devanand DP, Lee S, Luchsinger JA, Andrews H, Goldberg T, Huey ED, Schupf N, Manly J, Stern Y, Kreisl WC, et al. Intact global cognitive and olfactory ability predicts lack of transition to dementia. Alzheimers Dement. 2020;16(2):326–34. 31676234 PMC7007828 · DOI
  103. [118]Tu L, Lv X, Fan Z, Zhang M, Wang H, Yu X. Association of odor identification ability with Amyloid-β and tau burden: a systematic review and Meta-analysis. Front Neurosci. 2020;14: 586330. 33324151 PMC7726324 · DOI
  104. [119]Tian Q, Bilgel M, Moghekar AR, Ferrucci L, Resnick SM. Olfaction, cognitive impairment, and PET biomarkers in community-dwelling older adults. J Alzheimers Dis. 2022;86(3):1275–85. 35180111 PMC12163179 · DOI
  105. [120]Diez I, Ortiz-Terán L, Ng TSC, Albers MW, Marshall G, Orwig W, Kim CM, Bueichekú E, Montal V, Olofsson J, et al. Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging. Nat Commun. 2024;15(1):4809. 38844444 PMC11156945 · DOI
  106. [121]Klein J, Yan X, Johnson A, Tomljanovic Z, Zou J, Polly K, Honig LS, Brickman AM, Stern Y, Devanand DP, et al. Olfactory impairment is related to Tau Pathology and Neuroinflammation in Alzheimer’s Disease. J Alzheimers Dis. 2021;80(3):1051–65. 33646153 PMC8044007 · DOI
  107. [122]Ekström I, Josefsson M, Larsson M, Rönnlund M, Nordin S, Olofsson JK. Subjective olfactory loss in older adults concurs with long-term odor identification decline. Chem Senses. 2019;44(2):105–12. 30544138 · DOI
  108. [123]Stanciu I, Larsson M, Nordin S, Adolfsson R, Nilsson LG, Olofsson JK. Olfactory impairment and subjective olfactory complaints independently predict conversion to dementia: a longitudinal, population-based study. J Int Neuropsychol Soc. 2014;20(2):209–17. 24451436 · DOI
  109. [124]Welge-Lüssen A. Ageing, neurodegeneration, and olfactory and gustatory loss. B-ENT. 2009;5(Suppl 13):129–32. 20084814
  110. [125]Devanand DP, Lee S, Manly J, Andrews H, Schupf N, Masurkar A, Stern Y, Mayeux R, Doty RL. Olfactory identification deficits and increased mortality in the community. Ann Neurol. 2015;78(3):401–11. 26031760 PMC4546561 · DOI
  111. [126]Kaya E, Göker AE. Olfactory dysfunction: its association with subjective cognitive impairment in patients with major depression. J Nerv Ment Dis. 2022;210(3):172–8. 34690274 · DOI
  112. [127]Dong J, Zhan X, Sun H, Fang F, Wei Y. Olfactory dysfunction is associated with cognitive impairment in patients with obstructive sleep apnea: a cross-sectional study. Eur Arch Otorhinolaryngol. 2022;279(4):1979–87. 34988658 · DOI
  113. [128]Mahali M, Coolidge FL. On the relationship between neurocognitive measures and olfactory dysfunction in COVID-19 patients with and without anosmia. Brain Behav Immun Health. 2023;30:100632. 37215309 PMC10196905 · DOI
  114. [129]Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, Bell K, Stern Y, Mayeux R. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer’s disease at follow-up. Am J Psychiatry. 2000;157(9):1399–405. 10964854 · DOI
  115. [130]Mitrano DA, Houle SE, Pearce P, Quintanilla RM, Lockhart BK, Genovese BC, Schendzielos RA, Croushore EE, Dymond EM, Bogenpohl JW, et al. Olfactory dysfunction in the 3xTg-AD model of Alzheimer’s disease. IBRO Neurosci Rep. 2021;10:51–61. 33842910 PMC8019944 · DOI
  116. [131]Ziegler-Waldkirch S, Friesen M, Loreth D, Sauer JF, Kemna S, Hilse A, Erny D, Helm C, Prinz PDE. Seed-induced Aβ deposition alters neuronal function and impairs olfaction in a mouse model of Alzheimer’s disease. Mol Psychiatry. 2022;27(10):4274–84. 35869271 PMC9718674 · DOI
  117. [132]Attems J, Jellinger KA. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol. 2006;25(6):265–71. 17140156
  118. [133]Zhou X, Kumar P, Bhuyan DJ, Jensen SO, Roberts TL, Münch GW. Neuroinflammation in alzheimer’s disease: a potential role of nose-picking in pathogen entry via the olfactory system? Biomolecules 2023;13(11):1568. PMC10669446 38002250
  119. [134]GoodSmith MS, Wroblewski KE, Schumm LP, McClintock MK, Pinto JM. Association of APOE ε4 status with long-term declines in odor sensitivity, odor identification, and cognition in older US adults. Neurology. 2023;101(13):e1341–50. 37495381 PMC10558172 · DOI
  120. [135]Frank RA, Rybalsky K, Brearton M, Mannea E. Odor recognition memory as a function of odor-naming performance. Chem Senses. 2011;36(1):29–41. 20935066 · DOI
  121. [136]Kjelvik G, Saltvedt I, White LR, Stenumgård P, Sletvold O, Engedal K, Skåtun K, Lyngvær AK, Steffenach HA, Håberg AK. The brain structural and cognitive basis of odor identification deficits in mild cognitive impairment and Alzheimer’s disease. BMC Neurol. 2014;14:168. 25154749 PMC4236673 · DOI
  122. [137]Son G, Yoo SJ, Kang S, Rasheed A, Jung DH, Park H, Cho B, Steinbusch HWM, Chang KA, Suh YH, et al. Region-specific amyloid-β accumulation in the olfactory system influences olfactory sensory neuronal dysfunction in 5xFAD mice. Alzheimers Res Ther. 2021;13(1):4. 33397474 PMC7784287 · DOI
  123. [138]Yoo SJ, Son G, Bae J, Kim SY, Yoo YK, Park D, Baek SY, Chang KA, Suh YH, Lee YB, et al. Longitudinal profiling of oligomeric Aβ in human nasal discharge reflecting cognitive decline in probable Alzheimer’s disease. Sci Rep. 2020;10(1):11234. 32641719 PMC7343787 · DOI
  124. [139]Liu D, Lu J, Wei L, Yao M, Yang H, Lv P, Wang H, Zhu Y, Zhu Z, Zhang X, et al. Olfactory deficit: a potential functional marker across the Alzheimer’s disease continuum. Front Neurosci. 2024;18: 1309482. 38435057 PMC10907997 · DOI
  125. [140]Schubert CR, Carmichael LL, Murphy C, Klein BE, Klein R, Cruickshanks KJ. Olfaction and the 5-year incidence of cognitive impairment in an epidemiological study of older adults. J Am Geriatr Soc. 2008;56(8):1517–21. 18662205 PMC2587240 · DOI
  126. [141]Doty RL, Shaman P, Applebaum SL, Giberson R, Siksorski L, Rosenberg L. Smell identification ability: changes with age. Science. 1984;226(4681):1441–3. 6505700 · DOI
  127. [142]Rawson NE. Olfactory loss in aging. Sci Aging Knowl Environ. 2006;2006(5):pe6. 16469731 · DOI
  128. [143]Woodward MR, Amrutkar CV, Shah HC, Benedict RH, Rajakrishnan S, Doody RS, Yan L, Szigeti K. Validation of olfactory deficit as a biomarker of Alzheimer disease. Neurol Clin Pract. 2017;7(1):5–14. 28243501 PMC5310210 · DOI
  129. [144]Liu S, Jiang Z, Zhao J, Li Z, Li R, Qiu Y, Peng H. Disparity of smell tests in Alzheimer’s disease and other neurodegenerative disorders: a systematic review and meta-analysis. Front Aging Neurosci. 2023;15: 1249512. 37744388 PMC10512741 · DOI
  130. [145]Menon C, Westervelt HJ, Jahn DR, Dressel JA, O’Bryant SE. Normative performance on the brief smell identification test (BSIT) in a multi-ethnic bilingual cohort: a Project FRONTIER study. Clin Neuropsychol. 2013;27(6):946–61. 23634698 PMC3742676 · DOI
  131. [146]Doty RL. Olfactory dysfunction and its measurement in the clinic. World J Otorhinolaryngol Head Neck Surg. 2015;1(1):28–33. 29204537 PMC5698508 · DOI
  132. [147]Kim SM, Kim HR, Min HJ, Kim KS, Jin JC, Han DH. A novel olfactory threshold test for screening cognitive decline among elderly people. PLoS ONE. 2021;16(7): e0254357. 34252091 PMC8274884 · DOI
  133. [148]Finkel D, Pedersen NL, Larsson M. Olfactory functioning and cognitive abilities: a twin study. J Gerontol B Psychol Sci Soc Sci. 2001;56(4):P226–233. 11445609 · DOI
  134. [149]Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T. Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol. 2010;32(10):1062–7. 20437286 · DOI
  135. [150]Palmquist E, Larsson M, Olofsson JK, Seubert J, Bäckman L, Laukka EJ. A prospective study on risk factors for olfactory dysfunction in aging. J Gerontol Biol Sci Med Sci. 2020;75(3):603–10. PMC7021638 31724031 · DOI
  136. [151]Challakere Ramaswamy VM, Schofield PW. Olfaction and executive cognitive performance: a systematic review. Front Psychol. 2022;13: 871391. 35615205 PMC9125097 · DOI
  137. [152]Pais MV, Forlenza OV, Diniz BS. Plasma biomarkers of Alzheimer’s disease: a review of available assays, recent developments, and implications for clinical practice. J Alzheimers Dis Rep. 2023;7(1):355–80. 37220625 PMC10200198 · DOI
  138. [153]Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O’Bryant S, Shaw LM, Cho M, et al. Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape. Neuron. 2023;111(18):2781–99. 37295421 PMC10720399 · DOI · Paper page
  139. [154]Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, et al. Blood biomarkers to detect Alzheimer Disease in primary care and secondary care. JAMA. 2024;332(15):1245–57. 39068545 PMC11284636 · DOI · Paper page
  140. [155]Guo Q, Ping L, Dammer EB, Duong DM, Yin L, Xu K, Shantaraman A, Fox EJ, Golde TE, Johnson ECB, et al. Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease. Mol Neurodegener. 2024;19(1):67. 39380021 PMC11460197 · DOI
  141. [156]Verbeek E, Drewes YM, Gussekloo J. Visual impairment as a predictor for deterioration in functioning: the Leiden 85-plus study. BMC Geriatr. 2022;22(1):397. 35524168 PMC9074345 · DOI
  142. [157]Al-Namaeh M. Common causes of visual impairment in the elderly. Med Hypothesis Discov Innov Ophthalmol. 2021;10(4):191–200. 37641654 PMC10460237 · DOI
  143. [158]Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–85. 15078664 · DOI · Paper page
  144. [159]Bourne RRA, Flaxman SR, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(9):e888–97. 28779882 · DOI · Paper page
  145. [160]Zheng C, Zeng R, Wu G, Hu Y, Yu H: Beyond Vision: A View from Eye to Alzheimer’s Disease and Dementia. J Prev Alzheimers Dis. 2024;11(2):469–83. 38374754
  146. [161]Deardorff WJ, Liu PL, Sloane R, Van Houtven C, Pieper CF, Hastings SN, Cohen HJ, Whitson HE. Association of sensory and cognitive impairment with Healthcare utilization and cost in older adults. J Am Geriatr Soc. 2019;67(8):1617–24. 30924932 PMC6684393 · DOI
  147. [162]Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, Klein R, Tielsch JM, Vijan S, Saaddine J. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754–60. 17159036 · DOI
  148. [163]Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration–emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450–71. 17101537 PMC4853957 · DOI
  149. [164]Davis BM, Crawley L, Pahlitzsch M, Javaid F, Cordeiro MF. Glaucoma: the retina and beyond. Acta Neuropathol. 2016;132(6):807–26. 27544758 PMC5106492 · DOI
  150. [165]Marks R. Falls among the elderly and vision: A Narrative Review. Open Med J. 2014;1(1):54–65.
  151. [166]Whitson HE, Cronin-Golomb A, Cruickshanks KJ, Gilmore GC, Owsley C, Peelle JE, Recanzone G, Sharma A, Swenor B, Yaffe K, et al. American Geriatrics Society and National Institute on Aging Bench-to-Bedside Conference: sensory impairment and cognitive decline in older adults. J Am Geriatr Soc. 2018;66(11):2052–8. 30248173 PMC6410371 · DOI
  152. [167]Wu SZ, Masurkar AV, Balcer LJ. Afferent and efferent visual markers of Alzheimer’s Disease: a review and update in early stage disease. Front Aging Neurosci. 2020;12: 572337. 33061906 PMC7518395 · DOI
  153. [168]Prasad S, Galetta SL. Anatomy and physiology of the afferent visual system. Handb Clin Neurol. 2011;102:3–19. 21601061 · DOI
  154. [169]Vermersch A. Cortical control of saccades. Annals Neuroloa. 1995;37:557–67. 7755349 · DOI
  155. [170]Girard B, Berthoz A. From brainstem to cortex: computational models of saccade generation circuitry. Prog Neurobiol. 2005;77(4):215–51. 16343730 · DOI
  156. [171]London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9(1):44–53. 23165340 · DOI
  157. [172]Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci. 2007;48(5):2285–9. 17460292 · DOI
  158. [173]Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurol Neurosurg. 2011;113(7):523–6. 21454010 · DOI
  159. [174]Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2007;420(2):97–9. 17543991 · DOI
  160. [175]Gao L, Liu Y, Li X, Bai Q, Liu P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr. 2015;60(1):162–7. 25459918 · DOI
  161. [176]Chiu K, Chan TF, Wu A, Leung IY, So KF, Chang RC. Neurodegeneration of the retina in mouse models of Alzheimer’s disease: what can we learn from the retina? Age (Dordr). 2012;34(3):633–49. 21559868 PMC3337933 · DOI
  162. [177]Guo L, Duggan J, Cordeiro MF. Alzheimer’s disease and retinal neurodegeneration. Curr Alzheimer Res. 2010;7(1):3–14. 20205667 · DOI
  163. [178]Snyder PJ, Alber J, Alt C, Bain LJ, Bouma BE, Bouwman FH, DeBuc DC, Campbell MCW, Carrillo MC, Chew EY, et al. Retinal imaging in Alzheimer’s and neurodegenerative diseases. Alzheimers Dement. 2021;17(1):103–11. 33090722 PMC8062064 · DOI
  164. [179]Mirzaei N, Shi H, Oviatt M, Doustar J, Rentsendorj A, Fuchs D-T, Sheyn J, Black KL, Koronyo Y, Koronyo-Hamaoui M. Alzheimer’s retinopathy: seeing disease in the eyes. Front NeuroSci. 2020;14: 921. 33041751 PMC7523471 · DOI
  165. [180]Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer’s disease. N Engl J Med. 1986;315(8):485–7. 3736630 · DOI
  166. [181]Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer’s disease. Brain Res. 1989;501(2):364–72. 2819446 · DOI
  167. [182]Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer’s disease patients. Clin Neurophysiol. 2001;112(10):1860–7. 11595144 · DOI
  168. [183]Iseri PK, Altinaş O, Tokay T, Yüksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol. 2006;26(1):18–24. 16518161 · DOI
  169. [184]Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer’s disease. Ophthalmology. 1990;97(1):9–17. 2314849 · DOI
  170. [185]Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet. 2003;361(9365):1258–65. 12699953 · DOI
  171. [187]Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z. Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice. Am J Pathol. 2009;175(5):2099–110. 19834067 PMC2774073 · DOI · Paper page
  172. [188]Gasparini L, Crowther RA, Martin KR, Berg N, Coleman M, Goedert M, Spillantini MG. Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol Aging. 2011;32(3):419–33. 19356824 · DOI · Paper page
  173. [189]Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54(Suppl 1):S204–217. 20550967 PMC2991559 · DOI · Paper page
  174. [190]Schultz N, Byman E, Wennström M. Levels of retinal amyloid-β correlate with levels of retinal IAPP and hippocampal amyloid-β in neuropathologically evaluated individuals. J Alzheimers Dis. 2020;73(3):1201–9. 31884473 PMC7081096 · DOI
  175. [192]Naël V, Pérès K, Dartigues JF, Letenneur L, Amieva H, Arleo A, Scherlen AC, Tzourio C, Berr C, Carrière I, et al. Vision loss and 12-year risk of dementia in older adults: the 3 C cohort study. Eur J Epidemiol. 2019;34(2):141–52. 30610413 · DOI
  176. [193]Hanson RLW, Gale RP, Gouws AD, Airody A, Scott MTW, Akthar F, Waterson S, Wells MT, Wright AJ, Bell K, et al. Following the status of visual cortex over time in patients with macular degeneration reveals atrophy of visually deprived brain regions. Invest Ophthalmol Vis Sci. 2019;60(15):5045–51. 31800962 · DOI
  177. [194]Ferguson EL, Thoma M, Buto PT, Wang J, Glymour MM, Hoffmann TJ, Choquet H, Andrews SJ, Yaffe K, Casaletto K, et al. Visual impairment, eye conditions, and diagnoses of neurodegeneration and dementia. JAMA Netw Open. 2024;7(7):e2424539. 39078629 PMC11289698 · DOI
  178. [195]Lin H, Zhang L, Lin D, Chen W, Zhu Y, Chen C, Chan KC, Liu Y, Chen W. Visual restoration after cataract surgery promotes functional and structural brain recovery. EBioMedicine. 2018;30:52–61. 29548900 PMC5952227 · DOI
  179. [196]Pedersini CA, Miller NP, Gandhi TK, Gilad-Gutnick S, Mahajan V, Sinha P, Rokers B. White matter plasticity following cataract surgery in congenitally blind patients. Proc Natl Acad Sci U S A. 2023;120(19): e2207025120. 37126677 PMC10175850 · DOI
  180. [197]Sabel BA, Gao Y, Antal A. Reversibility of visual field defects through induction of brain plasticity: vision restoration, recovery and rehabilitation using alternating current stimulation. Neural Regen Res. 2020;15(10):1799–806. 32246620 PMC7513964 · DOI
  181. [198]Maharani A, Dawes P, Nazroo J, Tampubolon G, Pendleton N. Cataract surgery and age-related cognitive decline: a 13-year follow-up of the English Longitudinal Study of Ageing. PLoS ONE. 2018;13(10): e0204833. 30307960 PMC6181298 · DOI
  182. [199]Miyata K, Yoshikawa T, Morikawa M, Mine M, Okamoto N, Kurumatani N, Ogata N. Effect of cataract surgery on cognitive function in elderly: results of Fujiwara-Kyo Eye Study. PLoS ONE. 2018;13(2): e0192677. 29462175 PMC5819799 · DOI
  183. [200]Lad M, Sedley W, Griffiths TD. Sensory loss and risk of dementia. Neuroscientist. 2024;30(2):247–59. 36169300 PMC10928952 · DOI
  184. [201]Yoshida Y, Ono K, Sekimoto S, Umeya R, Hiratsuka Y. Impact of cataract surgery on cognitive impairment in older people. Acta Ophthalmol. 2024;102(4):e602–11. 38146059 · DOI
  185. [202]Hecht I, Kanclerz P, Tuuminen R. Secondary outcomes of lens and cataract surgery: more than just best-corrected visual acuity. Prog Retin Eye Res. 2023;95:101150. 36481168 · DOI
  186. [203]Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer’s: exploring disease in the retina. Acta Neuropathol. 2016;132:767–87. 27645291 PMC5106496 · DOI
  187. [204]Cabrera DeBuc D, Gaca-Wysocka M, Grzybowski A, Kanclerz P. Identification of retinal biomarkers in alzheimer’s disease using optical coherence tomography: recent insights, challenges, and opportunities. J Clin Med. 2019;8(7):996. 31323964 PMC6678943 · DOI
  188. [205]Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A. Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2012;109(22):8740–5. 22592800 PMC3365221 · DOI · Paper page
  189. [206]Cerquera-Jaramillo MA, Nava-Mesa MO, González-Reyes RE, Tellez-Conti C. de-la-Torre A: visual features in alzheimer’s disease: from basic mechanisms to clinical overview. Neural Plast. 2018;2018:2941783. 30405709 PMC6204169 · DOI
  190. [207]Sartucci F, Porciatti V. Psychophysiology and electrophysiology of the visual system. In: Psychophysiology methods. edn. Edited by Valeriani M, de Tommaso M. New York, NY: Springer US; 2024:115–156.
  191. [208]Molitor RJ, Ko PC, Ally BA. Eye movements in Alzheimer’s disease. J Alzheimers Dis. 2015;44(1):1–12. 25182738 PMC5332166 · DOI
  192. [209]Wilcockson TDW, Mardanbegi D, Xia B, Taylor S, Sawyer P, Gellersen HW, Leroi I, Killick R, Crawford TJ. Abnormalities of saccadic eye movements in dementia due to Alzheimer’s disease and mild cognitive impairment. Aging. 2019;11(15):5389–98. 31375642 PMC6710064 · DOI
  193. [210]Wolf A, Tripanpitak K, Umeda S, Otake-Matsuura M. Eye-tracking paradigms for the assessment of mild cognitive impairment: a systematic review. Front Psychol. 2023;14: 1197567. 37546488 PMC10399700 · DOI
  194. [211]López-Cuenca I, Nebreda A, García-Colomo A, Salobrar-García E, de Frutos-Lucas J, Bruña R, Ramírez AI, Ramirez-Toraño F, Salazar JJ, Barabash A, et al. Early visual alterations in individuals at-risk of Alzheimer’s disease: a multidisciplinary approach. Alzheimers Res Ther. 2023;15(1):19. 36694201 PMC9872347 · DOI
  195. [212]Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer’s disease. Am J Ophthalmol. 1987;104(2):113–20. 3618708 · DOI
  196. [213]Bernardin F, Schwan R, Lalanne L, Ligier F, Angioi-Duprez K, Schwitzer T, Laprevote V. The role of the retina in visual hallucinations: a review of the literature and implications for psychosis. Neuropsychologia. 2017;99:128–38. 28263800 · DOI
  197. [214]Cronin-Golomb A. Vision in Alzheimer’s disease. Gerontologist. 1995;35(3):370–6. 7622089 · DOI
  198. [215]Leroi I, Voulgari A, Breitner JC, Lyketsos CG. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry. 2003;11(1):83–91. 12527543 · DOI
  199. [216]Liu D, Zhang L, Li Z, Zhang X, Wu Y, Yang H, Min B, Zhang X, Ma D, Lu Y. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease. BMC Neurol. 2015;15:14. 25886372 PMC4342899 · DOI
  200. [217]Welge-Lüssen A, Dörig P, Wolfensberger M, Krone F, Hummel T. A study about the frequency of taste disorders. J Neurol. 2011;258(3):386–92. 20886348 · DOI

200 of 297 shown

Authors
Hong, S., Baek, S.-H., Lai, M. K. P., Arumugam, T. V., & Jo, D.-G.
Affiliations
  • Sungkyunkwan University (KR)
  • National University of Singapore (SG)
  • La Trobe University (AU)
Corresponding author
  • Arumugam, Thiruma V.
  • Jo, Dong-Gyu
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2024-12-04
Volume
19
Issue
1
Pages
93-93
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/s13024-024-00776-y
PMC
PMC11616278
OpenAlex
W4405016350
Cited by
76
References
314
Citations by year
2026: 43 · 2025: 33
FWCI
6.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Oceans and Fisheries (2021-KS211513)
  • National health and medical research council of Australia (2019100)
  • National Research Foundation of Korea (RS-2024-00345742, RS-2024-00399237, NRF-2022R1I1A1A01072791)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Sensory Systems › Olfactory and Sensory Function Studies
Keywords
Alzheimer's disease, sensory impairment, aging, olfactory dysfunction, taste disorders, hearing loss, visual impairment, tactile perception, retinal thinning, amyloid-beta, tau pathology, early biomarkers, early detection, neurodegeneration
MeSH terms
Aging, Alzheimer Disease, Humans, Sensation Disorders, Amyloid beta-Peptides, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review